Clinical trial Recruiting at 1 site Interventional Ages 20 to 60

Linoleic acid–rich oil versus blended oil for adults with insulin resistance

Official title: Role of Linoleic Acid in Cardiometabolic Health Beyond Its Lipid-lowering Effects, and Its Dietary and Pathophysiological Implications

Run by Pontificia Universidad Catolica de Chile · NCT07287514 · Data updated 2026-11-12

This trial will test whether taking a linoleic acid–rich oil daily for 8 weeks improves insulin resistance in adults who already have insulin resistance.

More Insulin Resistance trials

Quick facts

Study typeInterventional
Ages20 Years to 60 Years
SexAll
Enrollment120 (estimated)
SponsorPontificia Universidad Catolica de Chile
Academic / other
Locations1 site (Santiago, Santiago Metropolitan)
StatusRecruiting
StartedMay 13, 2025
Main results expectedOctober 2026
Study endsDecember 2026
Registry record updatedDecember 17, 2025
Trial IDNCT07287514 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 20–60 with documented insulin resistance (HOMA-IR > 2.6) and at least one cardiometabolic risk factor who are not diabetic and are not taking medications that affect lipids or insulin sensitivity are ideal candidates.

Probably not a fit

People with diagnosed diabetes, prior clinical cardiovascular disease, recent bariatric surgery, pregnancy or lactation, malabsorption disorders, or regular use of excluded medications or PUFA supplements are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In a single-blind, randomized, parallel-group intervention, adults with insulin resistance will be assigned to take either a linoleic acid–rich oil supplement or a control blended oil each day for 8 weeks while keeping their usual diet and lifestyle. The main outcome is change in insulin resistance measured by HOMA-IR, with secondary outcomes including fasting glucose and insulin, lipid profile, inflammatory and oxidative stress markers, and body composition. Participants are adults aged 20–60 with HOMA-IR > 2.6 and at least one cardiometabolic risk factor, and people with diabetes, prior cardiovascular disease, or on certain medications are excluded. The trial is conducted at a single clinical research center and aims to provide controlled randomized data on the metabolic effects of increasing dietary linoleic acid.

Why it matters

Potential benefit: If successful, this intervention could offer a simple dietary supplement approach to improve insulin sensitivity and related metabolic markers in people with insulin resistance.

How similar studies have gone: Observational studies and meta-analyses have linked higher linoleic acid intake to better lipid profiles and lower diabetes risk, but well-controlled randomized trials testing metabolic outcomes remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men and women aged 20 to 60 years.
* Insulin resistance (HOMA-IR \> 2.6).
* At least one cardiometabolic risk factor: abdominal obesity (waist circumference \> 90 cm in men or \> 80 cm in women); low HDL-cholesterol (\< 40 mg/dL in men or \< 50 mg/dL in women); elevated LDL-cholesterol (\> 70 / 100 / 130 mg/dL, according to estimated cardiovascular risk); or elevated blood pressure (≥ 130/85 mmHg).

Exclusion Criteria:

* Diabetes diagnosis.
* Severe psychiatric illness.
* Malabsorption disorders or previous bariatric surgery.
* Pregnancy or lactation.
* Previous clinical cardiovascular disease.
* Regular use of medications that could influence study outcomes, including:

lipid-lowering agents insulin sensitizers antihypertensive drugs anticoagulants antiretroviral therapy thyroid hormones oral corticosteroids immunosuppressants polyunsaturated fatty acid (PUFA) supplements.

* Fasting serum triglycerides ≥ 500 mg/dL or LDL-cholesterol ≥ 190 mg/dL.
* Body mass index (BMI) ≥ 35 kg/m².
* Very high blood pressure.
* Any additional condition that may limit adherence to the study.

Where it's running

  • Centro de Investigaciones Clínicas UC (CICUC) - Pontificia Universidad Católica de Chile
    Santiago, Santiago Metropolitan, Chile
    Recruiting

Study contacts

  • Principal investigator: Loni Berkowitz, PhD — Pontificia Universidad Catolica de Chile
  • Study coordinator: Loni Berkowitz, PhD
  • Email: lberkowi@uc.cl
  • Phone: 23543862

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.